Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Allergenis LLC is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is confined to 1 distinct examiner and 1 distinct art unit. Such a focused portfolio indicates a specific point of engagement with the patent office rather than a broad filing strategy. The 1 pending office action represents the company's current active examination phase.
The busiest examiner for this portfolio is GABEL, GAILENE, who holds 1 busiest examiner pending action. Since the total number of pending office actions is 1, GABEL, GAILENE is the sole official reviewing the company's current applications. The reliance on 1 distinct art unit means that the company's immediate patent prospects are subject to the specific examination standards of that particular group. Practitioners must tailor their approach to the specific preferences of GABEL, GAILENE to resolve the 1 pending office action successfully.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GABEL, GAILENE | 1 | 75.6% | +44.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18168853 | Threshold Assays For Cumulative Reactive Doses Of Peanut Antigens | GABEL, GAILENE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18168853 | Threshold Assays For Cumulative Reactive Doses Of Peanut Antigens | GABEL, GAILENE | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18168853 | Threshold Assays For Cumulative Reactive Doses Of Peanut Antigens | GABEL, GAILENE | 1678 | §103§112Other | Non-Final OA | — | Pending | Feb 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAllergenis LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gailene Gabel has the most, with 1 of Allergenis LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
